Presentation TCT 2025 TCT 488: Sex-Based Differences in Cardiovascular Outcomes With Achieved LDL-C <55 mg/dL: A Comparative Cohort Analysis Presenter: Mehmet Cilingiroglu October 28, 2025
Presentation TCT 2025 Optimizing PCI Outcomes After ACS: Lipid Modification Therapies - LDL, Lp(a) and Beyond Presenter: Marc P. Bonaca October 27, 2025
Presentation TCT 2025 TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI Presenter: Kunal Mahajan October 27, 2025
Presentation TCT 2025 TCT 470: Comparative Outcomes of Serum LDL Levels <55 mg/dL Versus 55–100 mg/dL for Primary Prevention of Undiagnosed Coronary Artery Disease: A Retrospective Cohort Study Presenter: Mehmet Cilingiroglu October 27, 2025
Presentation TCT 2025 TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study Presenter: Kunal Mahajan October 27, 2025
Presentation TCT 2025 ACS Pharma Trials On The Horizon: LDL Lowering Therapies Presenter: Angelo Oliva October 26, 2025